Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The target "ARF like GTPase 4A pseudogene 3" (ARL4AP3) does not appear to be a valid, recognized protein target in the scientific literature. It is likely a pseudogene, which are DNA sequences resembling functional genes but are generally not translated into functional proteins and are not considered drug targets. Pseudogenes often arise from gene duplication and subsequent accumulation of mutations that disable protein-coding capacity, making them not therapeutically actionable in the conventional sense. There is no evidence that pseudogenes like ARL4AP3 are considered drug targets, nor do they have recognizable aliases, molecular classifications, functions, or roles in disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ARF like GTPase 4A pseudogene 3 (ARL4AP3).